Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisotumab Vedotin in Locally Advanced or Metastatic Solid Tumors
NCT03485209Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2018
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of tisotumab vedotin in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), pancreatic cancer (PC), head and neck squamous cell carcinoma (HNSCC), sponsored by Pfizer. Started Jun 2018; status: active, not recruiting.
02
Drugs
tisotumab vedotin
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03485209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485209.